InterShunt Technologies announced it began an early feasibility study of its device for reducing heart failure symptoms.
Dr. Sitaramesh Emani and the Structural Heart Intervention Team at The Christ Hospital Health Network in Cincinnati, Ohio, performed the first procedure utilizing the technology. The study focuses on patients with heart failure with reduced ejection fraction (HFrEF).
Related: Neurent earns coverage win for chronic rhinitis treatment
“We’re excited to get this study started,” said Emani. “The first procedure went smoothly, and the patient went home the next day feeling well. It’s an encouraging start, and we’re hopeful this treatment can help many more people.”
Minneapolis-based InterShunt designed its device to reduce symptoms and improve quality of life. The device works by creating a small opening between the heart’s upper chambers to relieve pressure built up in heart failure. It uses a mechanical cutting method that avoids scarring and allows the heart to move naturally.
InterShunt said the proprietary catheter system securely captures and excises a defined piece of tissue from the interatrial septum. It results in a left-to-right atrial shunt that offloads elevated left atrial pressure.
“This first enrollment is a big step for our team and for people living with heart failure. We are incredibly thankful to the patient, their family, and the team at The Christ Hospital for making this possible.” said Harlee Sorkin, CEO of InterShunt Technologies. “Because the procedure leaves nothing behind in the heart, it avoids the risks of permanent implants and keeps future treatment options open.”
